{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:49:26Z","timestamp":1761166166942,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.anndiagpath.2022.151909","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T12:52:51Z","timestamp":1644238371000},"page":"151909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma"],"prefix":"10.1016","volume":"58","author":[{"given":"Evalyn E.A.P.","family":"Mulder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00eblle","family":"Verver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thom","family":"van der Klok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin J.","family":"de Wijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry P.P.","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"De Herdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berdine","family":"van der Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senada","family":"Koljenovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2022.151909_bb0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc.2017.43","article-title":"Melanoma: a global perspective","volume":"17","author":"Ossio","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.anndiagpath.2022.151909_bb0010","article-title":"Epidemiology of invasive cutaneous melanoma","volume":"20","author":"MacKie","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0030","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2015.12.002","article-title":"The rapidly evolving therapies for advanced melanoma\u2014towards immunotherapy, molecular targeted therapy, and beyond","volume":"99","author":"Zhu","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0040","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0045","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0050","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2018.02.022","article-title":"Risk stratification of sentinel node\u2013positive melanoma patients defines surgical management and adjuvant therapy treatment considerations","volume":"96","author":"Verver","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJMe1313690","article-title":"Clinical value of the sentinel-node biopsy in primary cutaneous melanoma","volume":"370","author":"Balch","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0065","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0070","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma - accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.seminoncol.2007.09.010","article-title":"Surgery and sentinel lymph node biopsy","volume":"34","author":"Faries","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0080","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","article-title":"Complications of sentinel lymph node biopsy for melanoma \u2013 a systematic review of the literature","volume":"43","author":"Moody","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000352092","article-title":"How long will I be blue? Prolonged skin staining following sentinel lymph node biopsy using intradermal patent blue dye","volume":"8","author":"Gumus","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0090","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons oncology group trial Z0011","volume":"25","author":"Lucci","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0095","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2016.08.014","article-title":"Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival","volume":"67","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/CMR.0b013e32835861f6","article-title":"The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival","volume":"22","author":"Parrett","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejca.2005.10.023","article-title":"High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma","volume":"42","author":"van Akkooi","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0120","article-title":"Fluorescence-guided surgery in colorectal cancer; a review on clinical results and future perspectives","author":"Galema","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0125","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1016\/S1470-2045(19)30317-1","article-title":"Latest developments in molecular tracers for fluorescence image-guided cancer surgery","volume":"20","author":"Hernot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.humpath.2020.08.010","article-title":"C-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations","volume":"105","author":"Ren","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0135","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/bjs.7538","article-title":"Seeing the invisible during surgery","volume":"98","author":"Vahrmeijer","year":"2011","journal-title":"Br J Surg"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1117\/1.JBO.24.12.120901","article-title":"Review of clinical trials in intraoperative molecular imaging during cancer surgery","volume":"24","author":"Lee","year":"2019","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0145","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.7150\/thno.15718","article-title":"Optical imaging of mesenchymal epithelial transition factor (MET) for enhanced detection and characterization of primary and metastatic hepatic tumors","volume":"6","author":"Esfahani","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0150","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.ajpath.2019.08.002","article-title":"The role of MET in melanoma and melanocytic lesions","volume":"189","author":"Zhou","year":"2019","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0155","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.3390\/ijms19123844","article-title":"HGF\/c-MET signaling in melanocytes and melanoma","volume":"19","author":"Czyz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-018-0795-z","article-title":"Role of the HGF\/c-MET tyrosine kinase inhibitors in metastasic melanoma","volume":"17","author":"Demkova","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0165","doi-asserted-by":"crossref","DOI":"10.1593\/neo.111102","article-title":"Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032","volume":"13","author":"Vergani","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0170","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/his.12169","article-title":"Impact of MET expression on outcome in BRAFV600E\/K advanced melanoma","volume":"63","author":"Jubb","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Timothy","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0180","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1755-148X.2011.00836.x","article-title":"Receptor tyrosine kinases and their activation in melanoma","volume":"24","author":"Easty","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0185","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Ravid","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0190","doi-asserted-by":"crossref","first-page":"13167","DOI":"10.18632\/oncotarget.7534","article-title":"Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma","volume":"7","author":"De Herdt","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0195","first-page":"13","article-title":"The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis","volume":"1","author":"Riker","year":"2008","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0200","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000071207","article-title":"Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas","volume":"65","author":"Cruz","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0205","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bjc.1993.422","article-title":"Expression of the c-Met\/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression","volume":"68","author":"Natali","year":"1993","journal-title":"Br J Cancer"},{"year":"2011","series-title":"Code for proper secondary use of human tissue in the Netherlands","author":"Grobbee","key":"10.1016\/j.anndiagpath.2022.151909_bb0210"},{"year":"2004","series-title":"Code of conduct for the use of data in health research","key":"10.1016\/j.anndiagpath.2022.151909_bb0215"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","article-title":"The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients","volume":"50","author":"van der Ploeg","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.04.022","article-title":"The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection","volume":"134","author":"Verver","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0230","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9107-6","article-title":"The met tyrosine kinase receptor in development and cancer","volume":"27","author":"Gentile","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2021.02.019","article-title":"Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-met-targeted probe in a preclinical xenograft model","volume":"332","author":"Liang","year":"2021","journal-title":"J Control Release"},{"year":"2021","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): cutaneous melanoma, version 2 (2021)","author":"National Comprehensive Cancer Network","key":"10.1016\/j.anndiagpath.2022.151909_bb0245"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0250","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.2010.33.1884","article-title":"Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis","volume":"29","author":"Valsecchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0255","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/ncomms8174","article-title":"Activating MET kinase rearrangements in melanoma and spitz tumours","volume":"6","author":"Yeh","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0260","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1002\/ijc.26487","article-title":"Association of Activated c-met with NRAS-mutated human melanomas: a possible avenue for targeting","volume":"131","author":"Chattopadhyay","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0265","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","article-title":"Crizotinib, a c-met inhibitor, prevents metastasis in a metastatic uveal melanoma model","volume":"12","author":"Surriga","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051104","article-title":"Dual targeting of CDK4\/6 and cMET in metastatic uveal melanoma","volume":"13","author":"Ohara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0275","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/0284186X.2020.1747636","article-title":"BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis","volume":"59","author":"Ny","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0280","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0285","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0290","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0295","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0300","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0305","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0315","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2159-8290.CD-15-0933","article-title":"Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance","volume":"6","author":"Miller","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0320","doi-asserted-by":"crossref","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0325","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI0215418","article-title":"Dysregulation of met receptor tyrosine kinase activity in invasive tumors","volume":"109","author":"Danilkovitch-Miagkova","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0330","first-page":"148","article-title":"Targeting MET in cancer therapy","volume":"3","author":"Mo","year":"2017","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0335","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0340","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","article-title":"Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies","volume":"22","author":"Krepler","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2022.151909_bb0345","first-page":"27","article-title":"Dendritic cell function in sentinel nodes","volume":"16","author":"Essner","year":"2002","journal-title":"Oncology (Williston Park)"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:00Z","timestamp":1761078840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913422000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":69,"alternative-id":["S1092913422000119"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151909","relation":{},"ISSN":["1092-9134"],"issn-type":[{"type":"print","value":"1092-9134"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151909"}}